|
JP5547656B2
(ja)
|
2008-01-15 |
2014-07-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｃｄ４７によって媒介される食作用を操作するための方法
|
|
HK1216647A1
(zh)
|
2012-12-12 |
2016-11-25 |
Vasculox Inc. |
治疗性cd47抗体
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
HUE047221T2
(hu)
|
2012-12-17 |
2020-04-28 |
Trillium Therapeutics Inc |
A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal
|
|
ES2931337T3
(es)
*
|
2014-07-31 |
2022-12-28 |
Univ Western Australia |
Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red
|
|
CA2964173A1
(en)
*
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
WO2016081423A1
(en)
*
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
TR201903891T4
(tr)
|
2014-12-05 |
2019-04-22 |
Regeneron Pharma |
Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
TWI719966B
(zh)
*
|
2015-03-04 |
2021-03-01 |
美商索倫多醫療公司 |
結合ｃｄ４７之抗體治療劑
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
PL3341015T5
(pl)
*
|
2015-08-26 |
2024-04-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym
|
|
WO2017044859A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
CN108348589B
(zh)
|
2015-09-18 |
2022-09-23 |
安驰肿瘤公司 |
治疗性cd47抗体
|
|
CA2999277A1
(en)
|
2015-09-21 |
2017-03-30 |
Surface Oncology, Inc. |
Anti-cd47 antibodies and methods of use
|
|
ES2988976T3
(es)
|
2015-11-27 |
2024-11-22 |
Cartherics Pty Ltd |
Células modificadas genéticamente y usos de estas
|
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
|
|
KR102472087B1
(ko)
|
2016-01-11 |
2022-11-29 |
포티 세븐, 인코포레이티드 |
인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
|
|
KR102833922B1
(ko)
*
|
2016-01-21 |
2025-07-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
면역조절제의 조합물에 의한 암의 치료
|
|
US20190091290A1
(en)
*
|
2016-04-15 |
2019-03-28 |
Trillium Therapeutics Inc. |
Macrophage stimulation in cd47 blockade therapy
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
EP3487522A4
(en)
|
2016-07-19 |
2020-04-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
|
KR102423086B1
(ko)
|
2016-10-20 |
2022-07-20 |
아이-맵 바이오파마 유에스 리미티드 |
새로운 cd47 단일클론 항체 및 그 용도
|
|
EP3529276A4
(en)
*
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
WO2018081897A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
CN108779179B
(zh)
*
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
US11267885B2
(en)
|
2017-01-26 |
2022-03-08 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
|
CN110612309A
(zh)
*
|
2017-03-27 |
2019-12-24 |
细胞基因公司 |
用于降低免疫原性的方法和组合物
|
|
CN110958888A
(zh)
*
|
2017-03-28 |
2020-04-03 |
延龄草治疗公司 |
Cd47阻断疗法
|
|
WO2019014398A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
|
|
NZ761568A
(en)
*
|
2017-08-02 |
2022-11-25 |
Phanes Therapeutics Inc |
Anti-cd47 antibodies and uses thereof
|
|
AU2018316742B2
(en)
|
2017-08-18 |
2025-04-10 |
Centessa Pharmaceuticals (Uk) Limited |
Binding agents
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
ES2932286T3
(es)
|
2017-10-18 |
2023-01-17 |
Forty Seven Inc |
Terapia contra el cáncer de ovarios basada en agente anti-CD47
|
|
AU2018358004A1
(en)
|
2017-11-01 |
2020-05-28 |
Hummingbird Bioscience Pte. Ltd. |
CD47 antigen-binding molecules
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
WO2019084692A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Trillium Therapeutics Inc. |
Cd47 blockade with radiation therapy
|
|
MA51208A
(fr)
|
2017-12-01 |
2020-10-07 |
Seattle Genetics Inc |
Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
WO2019200462A1
(en)
*
|
2018-04-16 |
2019-10-24 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN112566662A
(zh)
*
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
CN112673092B
(zh)
|
2018-07-11 |
2024-03-29 |
阿克蒂姆治疗有限公司 |
工程化的免疫刺激性细菌菌株及其用途
|
|
US20210324075A1
(en)
*
|
2018-08-13 |
2021-10-21 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
TWI830774B
(zh)
|
2018-08-31 |
2024-02-01 |
大陸商南京聖和藥業股份有限公司 |
抗cd47抗體及其應用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020091596A1
(en)
*
|
2018-10-29 |
2020-05-07 |
Umc Utrecht Holding B.V. |
Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
|
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
US20220017615A1
(en)
*
|
2018-12-03 |
2022-01-20 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47 antibody, preparation method therefor and uses thereof
|
|
JP2022523543A
(ja)
|
2019-03-06 |
2022-04-25 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
二機能性融合タンパク質及びその医薬的使用
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
WO2020247820A1
(en)
|
2019-06-07 |
2020-12-10 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
JP7317148B2
(ja)
*
|
2019-06-19 |
2023-07-28 |
レプ バイオファーマ カンパニー リミテッド |
抗ｃｄ４７抗体およびその使用
|
|
US11795210B2
(en)
|
2019-07-16 |
2023-10-24 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
EP4008727A4
(en)
*
|
2019-07-30 |
2024-01-17 |
Akeso Biopharma, Inc. |
ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODIES AND USE THEREOF
|
|
MX2022002613A
(es)
|
2019-09-03 |
2022-06-02 |
Myeloid Therapeutics Inc |
Metodos y composiciones para la integracion del genoma.
|
|
PH12022550489A1
(en)
*
|
2019-09-03 |
2022-12-12 |
Akeso Biopharma Inc |
Anti-cd47 monoclonal antibody and use thereof
|
|
PL4045083T3
(pl)
|
2019-10-18 |
2024-05-13 |
Forty Seven, Inc. |
Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
|
|
AU2020372522B2
(en)
*
|
2019-10-25 |
2024-08-15 |
WuXi Biologics Ireland Limited |
Novel anti-CD47 antibodies and uses thereof
|
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
|
US20230042316A1
(en)
*
|
2019-11-20 |
2023-02-09 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
MX2022007598A
(es)
|
2019-12-20 |
2022-09-23 |
Instil Bio Uk Ltd |
Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
|
|
US11845723B2
(en)
|
2019-12-24 |
2023-12-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CR20220396A
(es)
|
2020-02-14 |
2022-11-14 |
Jounce Therapeutics Inc |
Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
IL296829A
(en)
*
|
2020-04-02 |
2022-11-01 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Antigen-binding polypeptide binding to cd47, and use thereof
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
US20240016787A1
(en)
|
2020-11-03 |
2024-01-18 |
Rdiscovery, LLC |
Methods for treatment of cancer and phagocytosis-deficiency related diseases
|
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス，インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
|
KR20230142828A
(ko)
*
|
2020-11-04 |
2023-10-11 |
더 트러스티즈 오브 다트마우스 칼리지 |
허혈성 및/또는 재관류 손상의 치료/예방을 위한 vista 작용제
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
EP4296282A4
(en)
*
|
2021-02-19 |
2025-02-26 |
SHAPERON Inc. |
SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3218780A1
(en)
|
2021-05-11 |
2022-11-17 |
Daniel Getts |
Methods and compositions for genomic integration
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022297367B2
(en)
|
2021-06-23 |
2025-04-10 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
Diacylglyercol kinase modulating compounds
|
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
JP2024545193A
(ja)
|
2021-12-22 |
2024-12-05 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4499146A1
(en)
|
2022-03-24 |
2025-02-05 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
AU2023256670A1
(en)
|
2022-04-21 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|